ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
Chen JW, Jacot W, Cortés J, Krop IE, Dent S, Harbeck N, De Laurentiis M, Diéras V, Im YH, Stout TJ, Schimmoller F, Savage HM, Hutchinson KE, Wilson TR.
Chen JW, et al. Among authors: wilson tr.
Mol Oncol. 2023 Oct;17(10):2000-2016. doi: 10.1002/1878-0261.13416. Epub 2023 Mar 25.
Mol Oncol. 2023.
PMID: 36892268
Free PMC article.